Literature DB >> 23945222

Natriuretic peptides and fat metabolism.

Cedric Moro1.   

Abstract

PURPOSE OF REVIEW: Cardiac natriuretic peptides have emerged as potent metabolic hormones during the past decade. We here discuss recent work highlighting the potential importance of these hormones in metabolic physiology and diseases. RECENT
FINDINGS: Natriuretic peptides signal through a cyclic guanosine monophosphate pathway to convey their biological effects at the cell level. Similarly to cyclic adenosine monophosphate, activation of cyclic guanosine monophosphate signaling induces a browning of white fat and thermogenesis. Natriuretic peptides also enhance oxidative capacity and fat oxidation in skeletal muscle of mice and humans. The molecular mechanism involves an upregulation of mitochondrial fat oxidative capacity and respiration. This may be particularly relevant to relay the physiological adaptations of chronic exercise. Population-based studies indicate that circulating natriuretic peptides are lowered in obesity and predict type 2 diabetes. Recent work also directly link natriuretic peptides with type 2 diabetes through a gut-heart axis.
SUMMARY: Natriuretic peptides exhibit a wide range of biological actions to control metabolic homeostasis. Natriuretic peptides deficiency in obesity may trigger metabolic dysfunction and lead to type 2 diabetes. Increasing circulating natriuretic peptides level and tissue signaling may help to fight against metabolic complications of obesity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23945222     DOI: 10.1097/MCO.0b013e32836510ed

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  11 in total

1.  Sacubitril/valsartan: a cardiovascular drug with pluripotential actions.

Authors:  Steven G Chrysant; George S Chrysant
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

2.  Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?

Authors:  Rafael de la Espriella-Juan; Juan Sanchis; Antoni Bayés-Genís; Julio Núñez
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

Review 3.  Regulation of mitochondria function by natriuretic peptides.

Authors:  Mark Domondon; Anna B Nikiforova; Kristine Y DeLeon-Pennell; Daria V Ilatovskaya
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-11

Review 4.  Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function.

Authors:  Kailash N Pandey
Journal:  Physiol Genomics       Date:  2018-08-31       Impact factor: 3.107

Review 5.  Pathophysiology and treatment of obesity-related hypertension.

Authors:  Steven G Chrysant
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-03-24       Impact factor: 3.738

6.  Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension.

Authors:  Stefan Engeli; Rudi Stinkens; Tim Heise; Marcus May; Gijs H Goossens; Ellen E Blaak; Bas Havekes; Thomas Jax; Diego Albrecht; Parasar Pal; Uwe Tegtbur; Sven Haufe; Thomas H Langenickel; Jens Jordan
Journal:  Hypertension       Date:  2017-11-27       Impact factor: 10.190

7.  The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.

Authors:  R Stinkens; B W van der Kolk; J Jordan; T Jax; S Engeli; T Heise; J W Jocken; M May; C Schindler; B Havekes; N Schaper; D Albrecht; S Kaiser; N Hartmann; M Letzkus; T H Langenickel; G H Goossens; E E Blaak
Journal:  Sci Rep       Date:  2018-03-02       Impact factor: 4.379

Review 8.  Atrial Natriuretic Peptide31-67: A Novel Therapeutic Factor for Cardiovascular Diseases.

Authors:  Gustavo Jose Justo da Silva; Raffaele Altara; George W Booz; Alessandro Cataliotti
Journal:  Front Physiol       Date:  2021-07-08       Impact factor: 4.566

9.  The effect of surgical and non-surgical weight loss on N-terminal pro-B-type natriuretic peptide and its relation to obstructive sleep apnea and pulmonary function.

Authors:  Anne-Marie Gabrielsen; Torbjørn Omland; Mette Brokner; Jan Magnus Fredheim; Jens Jordan; Sverre Lehmann; May Brit Lund; Jøran Hjelmesæth; Dag Hofsø
Journal:  BMC Res Notes       Date:  2016-09-13

Review 10.  Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance.

Authors:  Iwona Kojta; Marta Chacińska; Agnieszka Błachnio-Zabielska
Journal:  Nutrients       Date:  2020-05-03       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.